Skip to main content
 

Caribou Biosciences Appoints Timothy F. Herpin, Ph.D. as Chief Business Officer

May 3, 2018

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading genome editing company, announced today that it has appointed Timothy F. Herpin, Ph.D. as its first Chief Business Officer. In this role, Tim will lead the company's efforts in the areas of strategic partnerships, licensing agreements, and other value creation opportunities.

“Tim’s knowledge and expertise are a perfect fit for Caribou as we continue to unlock the vast potential of our technology platform and drive new discoveries and applications,” said Rachel Haurwitz, Ph.D., President and Chief Executive Officer of Caribou. “Tim will play a critical role in advancing and fully capturing the value of our new, next-generation gene editing technology. He will also be an important leader in generating opportunities for our rapidly emerging pipeline of off-the-shelf CAR-T candidates and microbiome-based therapies."

Tim joins Caribou from AstraZeneca where he served as Vice President and Head of Transactions. In this role, he managed a group of business development professionals involved in the negotiation and execution of transactions in multiple disease areas. Among other deals, he was involved with AstraZeneca’s collaboration with Merck around its PARP inhibitor, the divestment of its antibacterial business to Pfizer, and the acquisition of a majority stake in Acerta Pharma. Prior to that, he served as Vice President of Strategic Partnering and Business Development for Oncology. Before AstraZeneca, Tim spent eight years in the business development organization at Bristol-Myers Squibb covering both search and evaluation, as well as transactions in multiple disease areas.

“Genome editing is revolutionizing all areas of science, from healthcare to agriculture to basic biological research. I am delighted to be joining a company that is at the forefront of this revolution and am excited to be a part of bringing the promise of Caribou’s technology to reality,” said Dr. Herpin.

Tim received his undergraduate degree in Chemistry from the École Polytechnique in France, his Ph.D. in Chemistry from the University College London, UK, and an M.B.A. from the NYU Stern School of Business.

Tim joins Barbara McClung, J.D., Chief Legal Officer; Steven Kanner, Ph.D., Chief Scientific Officer; and Dr. Haurwitz as officers of the Company.

About Caribou Biosciences, Inc.
Caribou is a leading company in CRISPR genome editing founded by pioneers of CRISPR-Cas9 biology. Caribou’s tools and technologies provide transformative capabilities to therapeutic development, agricultural biotechnology, industrial biotechnology, and basic and applied biological research.

Caribou offers licenses to its CRISPR-Cas9 foundational IP in multiple fields including research tools, internal research use, diagnostics, and industrial biotechnology. Interested companies may contact Caribou at licensing@cariboubio.com.

For more information about Caribou, visit www.cariboubio.com and follow the Company @CaribouBio. “Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

Contacts
Feinstein Kean Healthcare
Jessica Day, 617-761-6781
Jessica.day@fkhealth.com